BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

874 related articles for article (PubMed ID: 16107951)

  • 1. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
    Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
    J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; ViganĂ² P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
    Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
    Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy.
    Moore DM; Hogg RS; Braitstein P; Wood E; Yip B; Montaner JS
    Antivir Ther; 2006; 11(1):125-9. PubMed ID: 16518968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiological, immunological and virological characteristics, and disease progression of HIV-1/HCV-co-infected patients from a southern Brazilian population.
    Reiche EM; Bonametti AM; Morimoto HK; Morimoto AA; Wiechemann SL; Matsuo T; Vissoci Reiche F; Vogler IH
    Int J Mol Med; 2008 Mar; 21(3):387-95. PubMed ID: 18288387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
    Braitstein P; Zala C; Yip B; Brinkhof MW; Moore D; Hogg RS; Montaner JS
    J Infect Dis; 2006 Jan; 193(2):259-68. PubMed ID: 16362890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; Morsica G; Pizzaferri P; Ladisa N; Sighinolfi L; Chiodera A; Solmone M; Lalle E; Ippolito G; Monforte Ad; ;
    Antivir Ther; 2005; 10(1):109-17. PubMed ID: 15751768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV and hepatitis C coinfection.
    Matthews GV; Dore GJ
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?
    Rockstroh JK; Peters L; Grint D; Soriano V; Reiss P; Monforte Ad; Beniowski M; Losso MH; Kirk O; Kupfer B; Mocroft A;
    J Hepatol; 2013 Aug; 59(2):213-20. PubMed ID: 23583272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.
    Tedaldi EM; Baker RK; Moorman AC; Alzola CF; Furhrer J; McCabe RE; Wood KC; Holmberg SD;
    Clin Infect Dis; 2003 Feb; 36(3):363-7. PubMed ID: 12539079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival in HIV-infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database.
    Voirin N; Trépo C; Miailhes P; Touraine JL; Chidiac C; Peyramond D; Livrozet JM; Ritter J; Chevallier P; Fabry J; Allard R; Vanhems P
    J Viral Hepat; 2004 Nov; 11(6):559-62. PubMed ID: 15500557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy.
    Torre D; Tambini R; Cadario F; Barbarini G; Moroni M; Basilico C
    Clin Infect Dis; 2001 Nov; 33(9):1579-85. PubMed ID: 11588701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database.
    Zhou J; Dore GJ; Zhang F; Lim PL; Chen YM;
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1510-8. PubMed ID: 17645479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study.
    Anderson KB; Guest JL; Rimland D
    Clin Infect Dis; 2004 Nov; 39(10):1507-13. PubMed ID: 15546088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.